Recruiting PHASE3 INTERVENTIONAL 2-arm NCT04631471

Regeneration in Cervical Degenerative Myelopathy (RECEDE)

Regeneration in Cervical Degenerative Myelopathy - a Multi-centre, Double-blind, Randomised, Placebo Controlled Trial Assessing the Efficacy of Ibudilast as an Adjuvant Treatment to Decompressive Surgery for Degenerative Cervical Myelopathy

Sponsor: Cambridge University Hospitals NHS Foundation Trust

Conditions Myelopathy Spinal Cord Diseases

Interventions Cervical decompressive surgery Ibudilast Matching placebo

Updated 5 times since 2020 Last updated: Dec 24, 2021 Started: Dec 22, 2021 Primary completion: Sep 1, 2026 Completion: Sep 1, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04631471, this PHASE3 trial focuses on Myelopathy and Spinal Cord Diseases and remains actively recruiting participants. Sponsored by Cambridge University Hospitals NHS Foundation Trust, it has been updated 5 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Feb 2022 — Jul 2024 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Jan 2021 — Feb 2022 [monthly]

Not Yet Recruiting PHASE3
Dec 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cambridge University Hospitals NHS Foundation Trust

Data source: Cambridge University Hospitals NHS Foundation Trust

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cambridge, United Kingdom